Skip to main content

Aprea Therapeutics, Inc.

corporate_fare Company Profile

Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed APRE - Latest Insights

APRE
Apr 22, 2026, 5:01 PM EDT
Filing Type: S-3
Importance Score:
9
Aprea Therapeutics Registers Resale of 74.3M Shares and Warrants, Signaling Massive Potential Dilution
Sentiment: Negative
View Wiseek Article
APRE
Apr 20, 2026, 6:30 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Aprea Therapeutics Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
APRE
Apr 01, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
7
CFO Buys $25K in Warrants as Part of Recent Private Placement
Sentiment: Positive
View Wiseek Article
APRE
Apr 01, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
9
Director Richard Peters Invests $100K in Aprea Therapeutics' Critical Private Placement
Sentiment: Positive
View Wiseek Article
APRE
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
10
Aprea Therapeutics Secures $30M Oversubscribed Private Placement, Extends Runway, and Reports Positive Clinical Data
Sentiment: Positive
View Wiseek Article
APRE
Mar 30, 2026, 8:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Aprea Therapeutics Announces $30M Private Placement, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
APRE
Mar 19, 2026, 5:16 PM EDT
Filing Type: 424B3
Importance Score:
9
Aprea Therapeutics Registers 12.58 Million Shares for Resale, Representing 110% of Outstanding Stock; CEO and CFO Among Selling Stockholders
Sentiment: Negative
View Wiseek Article
APRE
Mar 16, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
8
Aprea Therapeutics Reports Going Concern Doubt, Nasdaq Delisting Risk, and Positive Early Clinical Data for APR-1051
Sentiment: Negative
View Wiseek Article
APRE
Mar 16, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Aprea Therapeutics Reports Early Clinical Success for APR-1051 and Secures Critical $8.7M Financing
Sentiment: Neutral
View Wiseek Article
APRE
Feb 20, 2026, 6:02 AM EST
Filing Type: S-3
Importance Score:
8
Aprea Therapeutics Registers Resale of Shares and Warrants from Recent Private Placement, Representing Over 100% of Outstanding Stock
Sentiment: Negative
View Wiseek Article
APRE
Feb 18, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Aprea Therapeutics Reports Second Unconfirmed Partial Response for WEE1 Inhibitor APR-1051 in Phase 1 Study
Sentiment: Positive
View Wiseek Article
APRE
Feb 02, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
7
CEO Gilad Oren Buys $25K in Shares Following Recent Private Placement
Sentiment: Positive
View Wiseek Article
APRE
Jan 29, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
9
Aprea Therapeutics Secures $5.6M Private Placement at Premium, Reports First Partial Response for WEE1 Inhibitor
Sentiment: Positive
View Wiseek Article
APRE
Jan 23, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
9
Aprea Therapeutics Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price
Sentiment: Negative
View Wiseek Article
APRE
Jan 09, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Aprea Therapeutics Updates Corporate Presentation with Early Clinical Data and Extended Cash Runway
Sentiment: Neutral
View Wiseek Article